NHS Dudley Health Economy Medicines Formulary
Home > 10 Musculoskeletal and joint diseases > 10.1 Drugs used in rheumatic diseases and gout > 10.1.3 Drugs that suppress the rheumatic disease process > Ankylosing spondylitis - golimumab - NICE TAG TA233

Ankylosing spondylitis - golimumab - NICE TAG TA233

1.1 Golimumab is recommended as an option for the treatment of severe, active ankylosing spondylitis in adults only if:

  • it is used as described for adalimumab and etanercept in 'Adalimumab, etanercept and infliximab for ankylosing spondylitis' (NICE technology appraisal guidance 143) and

  • the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose in accordance with the patient access scheme.

1.2 People currently receiving golimumab for the treatment of severe, active ankylosing spondylitis who do not fulfil the criteria for treatment with adalimumab and etanercept described in NICE technology appraisal guidance 143 should have the option to continue golimumab until they and their clinician consider it appropriate to stop.

 

https://www.nice.org.uk/guidance/TA233

Site by Devopa
© Copyright 2019 NHS. All rights reserved.